Mirae Asset Global ETFs Holdings’s Entrada Therapeutics TRDA Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$99.7K	Sell	13,551 -26	-0.2%	-$249	﹤0.01%	2829
2026 Q1	$171K	Buy	13,577 +329	+2%	+$3.77K	﹤0.01%	2436
2025 Q4	$136K	Buy	13,248 +140	+1%	+$1.18K	﹤0.01%	2534
2025 Q3	$76K	Sell	13,108 -2,280	-15%	-$13.3K	﹤0.01%	2793
2025 Q2	$103K	Buy	15,388 +589	+4%	+$4.74K	﹤0.01%	2598
2025 Q1	$134K	Buy	14,799 +624	+4%	+$7.78K	﹤0.01%	2498
2024 Q4	$245K	Buy	14,175 +608	+4%	+$11K	﹤0.01%	2281
2024 Q3	$217K	Buy	13,567 +2,178	+19%	+$34.3K	﹤0.01%	2341
2024 Q2	$162K	Buy	+11,389	New	+$162K	﹤0.01%	2362

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's TRDA Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Entrada Therapeutics (TRDA) stake by 0.19% in Q2 2026, selling an estimated $249 and leaving 13,551 shares worth $99.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2829.

Mirae Asset Global ETFs Holdings first reported a position in TRDA in Q2 2024 and has held it in 9 quarters since. The position peaked at $245K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Mirae Asset Global ETFs Holdings held 13,551 shares of Entrada Therapeutics worth $99.7K as of Q2 2026.
Mirae Asset Global ETFs Holdings sold 26 Entrada Therapeutics shares in Q2 2026, an estimated $249.
Entrada Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2829 holding.
Mirae Asset Global ETFs Holdings first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 9 quarters since.
Mirae Asset Global ETFs Holdings's Entrada Therapeutics position peaked at $245K in Q4 2024.
128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.